DENTSPLY SIRONA Inc (XRAY) Shares Bought by Cramer Rosenthal Mcglynn LLC

Cramer Rosenthal Mcglynn LLC boosted its holdings in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 10.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 799,748 shares of the medical instruments supplier’s stock after buying an additional 78,668 shares during the period. Cramer Rosenthal Mcglynn LLC’s holdings in DENTSPLY SIRONA were worth $52,647,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. NuWave Investment Management LLC purchased a new position in shares of DENTSPLY SIRONA in the 4th quarter worth about $121,000. Massey Quick Simon & CO. LLC purchased a new position in shares of DENTSPLY SIRONA in the 3rd quarter worth about $124,000. Focused Wealth Management Inc raised its holdings in shares of DENTSPLY SIRONA by 79.2% in the 4th quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock worth $171,000 after purchasing an additional 1,149 shares during the period. First Interstate Bank purchased a new position in shares of DENTSPLY SIRONA in the 3rd quarter worth about $164,000. Finally, Stock Yards Bank & Trust Co. purchased a new position in shares of DENTSPLY SIRONA in the 4th quarter worth about $203,000. 96.80% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of DENTSPLY SIRONA Inc (NASDAQ XRAY) opened at $58.42 on Tuesday. The company has a market capitalization of $13,420.00, a PE ratio of -8.49, a P/E/G ratio of 2.52 and a beta of 1.20. The company has a current ratio of 2.12, a quick ratio of 1.46 and a debt-to-equity ratio of 0.24. DENTSPLY SIRONA Inc has a twelve month low of $52.53 and a twelve month high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 EPS for the quarter, beating the consensus estimate of $0.81 by $0.01. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.06 billion. DENTSPLY SIRONA had a positive return on equity of 8.35% and a negative net margin of 39.39%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. research analysts predict that DENTSPLY SIRONA Inc will post 2.74 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Thursday, March 29th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.35 annualized dividend and a dividend yield of 0.60%. DENTSPLY SIRONA’s payout ratio is currently -5.09%.

In other DENTSPLY SIRONA news, Director Eric Brandt sold 6,409 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $68.04, for a total transaction of $436,068.36. Following the sale, the director now directly owns 12,073 shares in the company, valued at approximately $821,446.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.99% of the company’s stock.

XRAY has been the topic of a number of research reports. Credit Suisse Group cut their price objective on DENTSPLY SIRONA from $73.00 to $69.00 and set an “outperform” rating on the stock in a report on Friday, March 2nd. BidaskClub downgraded DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 2nd. JPMorgan Chase & Co. cut their price objective on DENTSPLY SIRONA from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, March 5th. Stephens initiated coverage on DENTSPLY SIRONA in a report on Tuesday, November 28th. They issued an “overweight” rating and a $75.00 price objective on the stock. Finally, HC Wainwright set a $63.00 price objective on DENTSPLY SIRONA and gave the stock a “hold” rating in a report on Monday, March 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $67.43.

COPYRIGHT VIOLATION WARNING: This article was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.themarketsdaily.com/2018/03/13/dentsply-sirona-inc-xray-shares-bought-by-cramer-rosenthal-mcglynn-llc.html.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply